文献速递泌尿男性生殖肿瘤

阿贝西利联合阿比特龙治疗转移性去势抵抗性前列腺癌:CYCLONE 2随机双盲安慰剂对照3期试验

Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial.
PubMed 文献 · Lancet Oncol · 2025-01-01

CYCLONE 2研究纳入393例转移性去势抵抗性前列腺癌患者,随机接受阿贝西利或安慰剂联合阿比特龙治疗。联合治疗组贫血、中性粒细胞减少及ALT升高等≥3级不良事件发生率更高,并出现3例治疗相关死亡(间质性肺病)。

要点

  • 阿贝西利联合阿比特龙未显著改善mCRPC患者的影像学无进展生存期。
  • 联合组≥3级贫血(14% vs 4%)、中性粒细胞减少(13% vs 1%)和ALT升高(9% vs 6%)更常见。
  • 联合组发生3例治疗相关死亡,均因间质性肺病。

核心结论

  • 在mCRPC人群中,CDK4/6与雄激素受体通路的双重抑制(阿贝西利联合阿比特龙)相比阿比特龙单药未改善影像学无进展生存期。
  • 联合治疗的安全性与此前两种药物各自报告的安全性一致。

研究设计与样本

  • CYCLONE 2是一项随机、双盲、安慰剂对照的3期研究,在12个国家的89家医院和学术/私人研究中心开展。
  • 共筛选515例患者,随机分配393例:阿贝西利联合阿比特龙组206例,安慰剂联合阿比特龙组187例。
  • 研究分三部分:第一部分为四臂安全性及剂量探索导入期,确定推荐2期剂量为阿贝西利200 mg每日两次;第二、三部分按1:1随机分配至阿贝西利(推荐2期剂量)或安慰剂联合标准阿比特龙+泼尼松/泼尼松龙。
  • 主要终点为研究者评估的影像学无进展生存期,在意向治疗人群(所有研究部分)中分析。

主要发现

  • 阿贝西利联合阿比特龙组最常见的≥3级不良事件为贫血(28/206,14% vs 8/185,4%)、中性粒细胞减少(26/206,13% vs 1/185,1%)和丙氨酸氨基转移酶升高(18/206,9% vs 12/185,6%)。
  • 严重不良事件发生率:阿贝西利联合阿比特龙组91/206(44%),安慰剂联合阿比特龙组68/185(37%)。
  • 阿贝西利联合阿比特龙组发生3例治疗相关死亡,均因间质性肺病。

临床怎么用

  • 对于mCRPC患者,不推荐在阿比特龙基础上常规联合阿贝西利,因该组合未改善影像学无进展生存期且增加毒性。
  • 使用阿贝西利联合阿比特龙时需密切监测贫血、中性粒细胞减少、肝酶升高及间质性肺病。

局限性

  • 研究未达到主要终点,未报告总生存期等其他疗效终点数据。
  • 入组人群以白人为主(74%),其他种族代表性有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Abemaciclib, a potent CDK4 and CDK6 inhibitor, has shown antitumour activity in prostate cancer models and in patients with metastatic castration-resistant prostate cancer (mCRPC) who have been heavily treated. We aimed to evaluate the safety and efficacy of abemaciclib in combination with abiraterone in patients with mCRPC. METHODS: CYCLONE 2 was a randomised, double-blind, placebo-controlled, phase 3 study done in 89 hospitals and academic and private research centres in 12 countries. All study parts had identical eligibility criteria, and used block randomisation with the same stratification factors (previous docetaxel treatment, presence of measurable disease, and type of progression). Participants were adults aged 18 years and older with histologically confirmed adenocarcinoma of the prostate and metastatic disease as documented by bone scans, CT scans, or MRI scans, and radiographic or PSA progression during continuous androgen deprivation therapy. Previous docetaxel for metastatic castration-sensitive prostate cancer was permitted; previous abiraterone, apalutamide, enzalutamide, darolutamide, or CDK4 and CDK6 inhibitors were exclusionary. The trial was conducted in three parts. Part 1 was a four-arm, placebo-controlled safety and dose-finding lead-in to determine the recommended phase 2 dose of abemaciclib with abiraterone. Participants were randomly assigned (2:2:1:1) to receive abiraterone (1000 mg orally once daily) and prednisone or prednisolone (5 mg orally twice daily) with either abemaciclib at 150 mg or 200 mg orally twice daily or with matching placebo (150 mg or 200 mg twice daily). In part 2 and part 3, patients were randomly assigned (1:1) to standard abiraterone and prednisone or prednisolone plus either abemaciclib at the recommended phase 2 dose or matching placebo. Patients, investigators, and sponsor were masked to treatment assignment. The primary outcome, investigator-assessed radiographic progression-free survival, was analysed in the intention-to-treat (participants from all study parts) population. Patients who received at least one dose of abiraterone, abemaciclib, or placebo were included in the safety population. This trial is registered at ClinicalTrials.gov, NCT03706365, and is completed. FINDINGS: Between Nov 26, 2018, and July 20, 2022, 515 patients were screened for eligibility, 393 of whom were randomly assigned, 206 patients to abemaciclib plus abiraterone and 187 to placebo plus abiraterone. The median age was 70·0 years (IQR 63·0-76·0). 289 (74%) of 393 patients identified as White, 80 (20%) as Asian, 17 (4%) as Black or African American, and seven (2%) as multiple race or not reported. The highest tested dose of 200 mg abemaciclib administered twice daily was chosen as the recommended phase 2 dose. The median follow-up time was 26·3 months (IQR 22·1-48·2) for the abemaciclib plus abiraterone group and 25·6 months (22·1-40·8) for the placebo plus abiraterone group. The primary endpoint of radiographic progression-free survival was not met: radiographic progression-free survival events were reported in 92 (45%) of 206 patients in the abemaciclib plus abiraterone group and 95 (51%) of 187 patients in the placebo plus abiraterone group (HR 0·83 [95% CI 0·62-1·11]; p=0·21). Median radiographic progression-free survival was 22·0 months (95% CI 19·3-27·5) for abemaciclib plus abiraterone and 20·3 months (16·5-24·4) for placebo plus abiraterone. The most common grade 3 or higher adverse events reported in the abemaciclib plus abiraterone group were anaemia (28 [14%] of 206 vs eight [4%] of 185 in the placebo plus abiraterone group), neutropenia (26 [13%] vs one [1%]), and alanine aminotransferase increase (18 [9%] vs 12 [6%]). Serious adverse events occurred in 91 (44%) of 206 patients in the abemaciclib plus abiraterone group and in 68 (37%) of 185 patients in the placebo plus abiraterone group. There were three treatment-related deaths due to interstitial lung disease in the abemaciclib plus abiraterone group. INTERPRETATION: Dual inhibition of CDK4 and CDK6 and the androgen receptor pathway with abemaciclib plus abiraterone did not improve radiographic progression-free survival compared with abiraterone alone in the CYCLONE 2 study population with mCRPC. Safety of the combination was consistent with the previously reported safety of the individual drugs. Additional research is required to identify effective combination therapies for patients with mCRPC, especially in those presenting with adverse prognostic characteristics. FUNDING: Eli Lilly.

来源:Lancet Oncol,查看原文。版权归原作者所有。

引用

  1. Smith M, Piulats J, Todenhöfer T, et al. Abemaciclib plus abiraterone in patients with metastatic castration-resistant prostate cancer (CYCLONE 2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 2025. PMID: 41167216. doi:10.1016/S1470-2045(25)00475-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。